Thalidomide in agnogenic and secondary myelofibrosis

Letizia Canepa, Filippo Ballerini, Riccardo Varaldo, Sabrina Quintino, Lizia Reni, Marino Clavio, Maurizio Miglino, Ivana Pierri, Marco Gobbi

Research output: Contribution to journalArticlepeer-review


Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.

Original languageEnglish
Pages (from-to)313-315
Number of pages3
JournalBritish Journal of Haematology
Issue number2
Publication statusPublished - 2001


  • Antiangiogenesis
  • Myelofibrosis
  • Myeloproliferative disorders
  • Thalidomide

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Thalidomide in agnogenic and secondary myelofibrosis'. Together they form a unique fingerprint.

Cite this